Incretin-based Drugs Market Size, Trends, Share, Growth, and Opportunity Forecast, 2023 - 2030 Global Industry Analysis by Drug Type (Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), By Route of Administration (Oral, and Parenteral), By Indication (Type-2 Diabetes, and Chronic Overweight Management), by Distribution Channel (Hospital Pharmacy, Offline Retail Stores, and Online Retail Stores), and by Geography (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

By Drug Type

·         Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

·         Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

By Route of Administration

·         Oral

·         Parenteral

By Indication

·         Type-2 Diabetes

·         Chronic Overweight Management

By Distribution Channel

·         Hospital Pharmacy

·         Offline Retail Stores

·         Online Retail Stores

By Geography

·         North America

·         Europe

·         Asia Pacific

·         South America

·         Middle East & Africa

Companies Profiled

·         GlaxoSmithKline

·         Johnson & Johnson

·         Merck & Co

·         AstraZeneca

·         Novartis AG

·         Eli Lilly and Company

·         Boehringer

·         Takeda Pharmaceutical Company

·         Sanofi

·         Sun Pharmaceutical

·         Bristol-Myers Squibb

·         Pfizer

·         Bayer AG

·         Roche

·         AbbVie

·         Amgen

·         Teva Pharmaceuticals Ltd.

·         Mylan

·         Lupin Pharmaceutical

·         KraftPal Technologies